Nanomol Technologies has recently been accredited as a pharmaceutical laboratory by the Spanish Agency for Medicines and Health Products (AEMPS). This recognition will allow the company to expand its capabilities in the development of innovative drugs, ensuring the quality and safety of its products.
Founded in 2010 by researchers from the Materials Science Institute of Barcelona (ICMAB CSIC), the company excels in the engineering and characterization of materials in the form of small particles. Located in the UAB Research Park , the company maintains a close collaboration with scientific and technical services, academic research groups and companies in the biotechnology, pharmaceutical and chemical sectors; fact that allows the company to offer services and innovative technologies in the international arena.
Accreditation as a pharmaceutical laboratory is a big step forward for Nanomol Technologies, as it will allow them to continue their work of research and development of advanced treatments. Thanks to the GMP (Good Manufacturing Practices) certification granted by the AEMPS, the company now meets the highest quality standards in its production and control processes for pharmaceutical products in the European Union . This accreditation guarantees that its products are manufactured under strict quality and safety standards, thus ensuring maximum reliability in the production of medicines and complying with the most rigorous regulatory requirements in the international arena.
Nanomol Technologies actively participates in the Industrial Doctorates Plan of the Generalitat de Catalunya, with three applied research projects that reinforce its commitment to innovation . The company's applied and strategic research within the framework of Industrial Doctorates has a direct impact on the improvement of public health , the advancement of biomolecular therapies and innovation in drug distribution systems, contributing significantly to the quality of life of the patients.
The first project, awarded in 2018 , focuses on the development of new nanoformulations for the topical administration of dermatological actives, with the aim of improving the effectiveness and safety of topical treatments . The second project, awarded in 2020 , works on the synthesis of new vesicular systems for the integration of biomolecules. This research is aimed at creating innovative vesicular systems that allow the efficient incorporation of biomolecules, thus improving biomolecular therapies . Finally, the third project, also awarded in 2020 , focuses on the synthesis and characterization of nanovesicles as new delivery systems for biomolecules. This project seeks to ensure a precise and effective distribution of biomolecules within the body, improving their therapeutic effectiveness.
The Industrial Doctorates Plan facilitates collaboration between the academic and business sectors, encouraging applied research with a great potential for impact on public health. This synergy between academic research and industrial needs drives the development of innovative products that can transform the pharmaceutical market, offering advanced medical solutions and improving the health and well-being of the population.
